Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

In a few short years, excitement about groundbreaking anti-obesity drugs made Novo Nordisk Europe’s most highly ... s opportunity to beat Eli Lilly’s Zepbound, which was approved in November ...

We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...

Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new ...

This was CNBC’s live blog covering all the latest news, views and action on Day 4 of the World Economic Forum in Davos, ...

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk ... failure drugs across the U.S., the five main European markets and Japan totaled $13.5 billion ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Semaglutide sells for $997 a month when branded under Ozempic and $1,349 a month for Wegovy. The haircut to Ozempic may have a spillover effect on competitor drugs from Eli Lilly — Mounjaro and ...

Eli Lilly and Company’s competing weight-loss drug, Zepbound (tirzepatide), could ... from more than 100 companies across the US, Europe, and China before deciding to license Sciwind’s molecules.